Antibiotics to treat diseases caused by Helicobacter

Summary of the technology

CSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical
derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the
bacterial load and even eradicate gastric infections caused by it.

Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent
licence agreement.
An offer for Patent Licensing

CSIC - Consejo Superior de Investigaciones Científicas
CSIC - Consejo Superior de Investigaciones Científicas

Fighting gastric infections without resistance


Figure 1: benzo [c] [1,2,5]oxadiazol The bacterium Helicobacter pylori (Hp) causes asymptomatic infections in the gastric mucosa that can induce chronic gastritis, ulcers even gastric cáncer. So far, convencional therapies are aggressive and the rate of eradication is decreasing, as Hp is increasingly resistant to such treatment.
Derivatives of benzo [c] [1,2,5]oxadiazol (Figure 1) are antimicrobials that act individually (without combination with other drugs) and selectively, attack a specific enzyme of the bacterium, its flavodoxine. In humans the enzyme is not present, so possible secondary damage is avoided.
The results obtained in mice have been, reduced rates of gastric colonization of Hp and even eradication in up to 60% of mouses.

Main innovations and advantages


· New antibiotics without known resistances.
· Efficacy in resistant strains.
· Safety: No toxicity at their active concentrations.
· Low cost synthesis.
· Bactericidal activity at low concentrations.
· Current status, in vitro: toxicity in cells and in vivo: both toxicity andefficacy test in mouses.

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Chemical Technology and Engineering
  • Biological Sciences
  • Medicine, Human Health
  • Dentristry / Odontology, Stomatology Technology
  • Medical Technology / Biomedical Engineering
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Medical Biomaterials
  • In vitro Testing, Trials Technology
  • Protecting Man and Environment
  • Medical/health
  • In vitro Testing, Trials Market
  • Medical Health related
  • Therapeutic
  • Pharmaceuticals/fine chemicals
  • Clinical Medicine
  • Gastroenterology
  • Internal medicine
  • helicobacter pilory
  • gastritis

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support